- Home
- XFOR vs CRDL Comparison
XFOR vs CRDL Comparison
Compare XFOR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- CRDL
- Stock Information
- Founded
- XFOR 2014
- CRDL 2017
- Country
- XFOR United States
- CRDL Canada
- Employees
- XFOR N/A
- CRDL N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XFOR Health Care
- CRDL Health Care
- Exchange
- XFOR Nasdaq
- CRDL Nasdaq
- Market Cap
- XFOR 84.3M
- CRDL 126.5M
- IPO Year
- XFOR N/A
- CRDL N/A
- Fundamental
- Price
- XFOR $3.29
- CRDL $1.14
- Analyst Decision
- XFOR Strong Buy
- CRDL Strong Buy
- Analyst Count
- XFOR 3
- CRDL 2
- Target Price
- XFOR $34.17
- CRDL $9.00
- AVG Volume (30 Days)
- XFOR 1.0M
- CRDL 706.5K
- Earning Date
- XFOR 11-12-2025
- CRDL 11-13-2025
- Dividend Yield
- XFOR N/A
- CRDL N/A
- EPS Growth
- XFOR N/A
- CRDL N/A
- EPS
- XFOR N/A
- CRDL N/A
- Revenue
- XFOR $32,774,000.00
- CRDL N/A
- Revenue This Year
- XFOR $1,313.84
- CRDL N/A
- Revenue Next Year
- XFOR N/A
- CRDL N/A
- P/E Ratio
- XFOR N/A
- CRDL N/A
- Revenue Growth
- XFOR 5721.31
- CRDL N/A
- 52 Week Low
- XFOR $1.35
- CRDL $0.77
- 52 Week High
- XFOR $26.83
- CRDL $2.44
- Technical
- Relative Strength Index (RSI)
- XFOR 52.53
- CRDL 47.89
- Support Level
- XFOR $2.88
- CRDL $1.06
- Resistance Level
- XFOR $3.37
- CRDL $1.10
- Average True Range (ATR)
- XFOR 0.37
- CRDL 0.06
- MACD
- XFOR -0.10
- CRDL 0.01
- Stochastic Oscillator
- XFOR 33.47
- CRDL 52.94
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.